Claudia C Friedrich1,2,3, Yunfeng Lin1,4,5, Alexander Krannich6, Yinan Wu6, Joseph P Vacanti1,2, Craig M Neville1,2,4. 1. Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA. 2. Department of Surgery, Massachusetts General Hospital, Boston, MA, USA. 3. Department of Anesthesiology and Intensive Care Medicine, Campus Virchow Klinikum and Campus Charité Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany. 4. Department of Orthopaedics, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 5. State Key Laboratory of Oral Diseases, West China College of Stomatology, Sichuan University, Chengdu, China. 6. Department of Biostatistics, Clinical Research Unit, Charité Universitätsmedizin Berlin, Berlin, Germany.
Abstract
OBJECTIVES: Creation of functional, durable vasculature remains an important goal within the field of regenerative medicine. Engineered biological vasculature has the potential to restore or improve human tissue function. We hypothesized that the pleotropic effects of insulin-like growth factor 1 (IGF1) would enhance the engineering of capillary-like vasculature. MATERIALS AND METHODS: The impact of IGF1 upon vasculogenesis was examined in in vitro cultures for a period of up to 40 days and as subcutaneous implants within immunodeficient mice. Co-cultures of human umbilical vein endothelial cells and human bone marrow-derived mesenchymal stem cells in collagen-fibronectin hydrogels were supplemented with either recombinant IGF1 protein or genetically engineered cells to provide sustained IGF1. Morphometric analysis was performed on the vascular networks that formed in four concentrations of IGF1. RESULTS: IGF1 supplementation significantly enhanced de novo vasculogenesis both in vitro and in vivo. Effects were long-term as they lasted the duration of the study period, and included network density, vessel length, and diameter. Bifurcation density was not affected. However, the highest concentrations of IGF1 tested were either ineffective or even deleterious. Sustained IGF1 delivery was required in vivo as the inclusion of recombinant IGF1 protein had minimal impact. CONCLUSION: IGF1 supplementation can be used to produce neovasculature with significantly enhanced network density and durability. Its use is a promising methodology for engineering de novo vasculature to support regeneration of functional tissue.
OBJECTIVES: Creation of functional, durable vasculature remains an important goal within the field of regenerative medicine. Engineered biological vasculature has the potential to restore or improve human tissue function. We hypothesized that the pleotropic effects of insulin-like growth factor 1 (IGF1) would enhance the engineering of capillary-like vasculature. MATERIALS AND METHODS: The impact of IGF1 upon vasculogenesis was examined in in vitro cultures for a period of up to 40 days and as subcutaneous implants within immunodeficient mice. Co-cultures of human umbilical vein endothelial cells and human bone marrow-derived mesenchymal stem cells in collagen-fibronectin hydrogels were supplemented with either recombinant IGF1 protein or genetically engineered cells to provide sustained IGF1. Morphometric analysis was performed on the vascular networks that formed in four concentrations of IGF1. RESULTS:IGF1 supplementation significantly enhanced de novo vasculogenesis both in vitro and in vivo. Effects were long-term as they lasted the duration of the study period, and included network density, vessel length, and diameter. Bifurcation density was not affected. However, the highest concentrations of IGF1 tested were either ineffective or even deleterious. Sustained IGF1 delivery was required in vivo as the inclusion of recombinant IGF1 protein had minimal impact. CONCLUSION:IGF1 supplementation can be used to produce neovasculature with significantly enhanced network density and durability. Its use is a promising methodology for engineering de novo vasculature to support regeneration of functional tissue.
Authors: Olga Tsigkou; Irina Pomerantseva; Joel A Spencer; Patricia A Redondo; Alison R Hart; Elisabeth O'Doherty; Yunfeng Lin; Claudia C Friedrich; Laurence Daheron; Charles P Lin; Cathryn A Sundback; Joseph P Vacanti; Craig Neville Journal: Proc Natl Acad Sci U S A Date: 2010-02-02 Impact factor: 11.205
Authors: Chung-Jung Chiu; Yvette P Conley; Michael B Gorin; Gary Gensler; Chao-Qiang Lai; Fu Shang; Allen Taylor Journal: Invest Ophthalmol Vis Sci Date: 2011-11-25 Impact factor: 4.799
Authors: Johanna E Lähteenvuo; Markku T Lähteenvuo; Antti Kivelä; Carolina Rosenlew; Annelie Falkevall; Joakim Klar; Tommi Heikura; Tuomas T Rissanen; Elisa Vähäkangas; Petra Korpisalo; Berndt Enholm; Peter Carmeliet; Kari Alitalo; Ulf Eriksson; Seppo Ylä-Herttuala Journal: Circulation Date: 2009-02-02 Impact factor: 29.690
Authors: Anthony Cannavicci; Qiuwang Zhang; Si-Cheng Dai; Marie E Faughnan; Michael J B Kutryk Journal: Can J Physiol Pharmacol Date: 2018-12-04 Impact factor: 2.273
Authors: Juan M Colazo; Brian C Evans; Angel F Farinas; Salam Al-Kassis; Craig L Duvall; Wesley P Thayer Journal: Tissue Eng Part B Rev Date: 2019-08 Impact factor: 6.389
Authors: Claudia C Friedrich; Yunfeng Lin; Alexander Krannich; Yinan Wu; Joseph P Vacanti; Craig M Neville Journal: Cell Prolif Date: 2017-11-07 Impact factor: 6.831
Authors: Wei Cao; Marco N Helder; Nathalie Bravenboer; Gang Wu; Jianfeng Jin; Christiaan M Ten Bruggenkate; Jenneke Klein-Nulend; Engelbert A J M Schulten Journal: Curr Osteoporos Rep Date: 2020-10 Impact factor: 5.096